Type 1 Diabetes: Clinical Breakdown: Autoimmune Pathophysiology, Absolute Insulin Deficiency, Diagnostic Criteria, Diabetic Ketoacidosis (DKA), and Lifelong Management
A clinical reference on T-cell-mediated beta-cell destruction, the diagnostic thresholds including autoantibodies and C-peptide, staged autoimmune progression, the metabolic route into ketoacidosis, and basal-bolus replacement.
Submitted research brief - Submitted to OwieClear; written with an AI assistant - November 2026
Read this first. This document was written outside OwieClear and has not been reviewed by a clinician. We publish it so you can read the source for yourself. It is educational and is not medical advice. Where our own pages disagree with it, follow our pages, which cite their sources, and ask a healthcare professional about anything that affects your care.
What we found that needs correcting
- This is an accurate and well-structured clinical reference. The T-cell framing, the diagnostic table including C-peptide, and the metabolic explanation of ketoacidosis are all correct, and including C-peptide alongside autoantibodies is better than most consumer-facing material manages. The notes below add the clinical detail that sits around the mechanism.
- One typographical point: the pathophysiology section writes Inselitis where the term is insulitis.
- The diagnostic table omits the fasting glucose threshold of 126 mg/dL or higher, which is one of the standard criteria. It is also worth noting that A1C can underestimate rapid-onset type 1, because glucose may have been raised for only a few weeks, so a normal or borderline A1C does not exclude the diagnosis in a symptomatic person.
- C-peptide needs one interpretive caveat: it should be measured alongside a simultaneous glucose, because a low value when glucose is also low means little. A small share of people with clinical type 1 are antibody-negative, and C-peptide becomes the more useful discriminator there.
- The staged progression is described in prose but not as the formal staging now in use. Stage 1 is two or more autoantibodies with normal glucose; stage 2 is autoantibodies with dysglycemia and no symptoms; stage 3 is clinical onset. This matters clinically, because teplizumab is licensed for stage 2 and delays progression by a median of around two years.
- Adult presentation deserves a section. Roughly half of new type 1 diagnoses are in adults, and adults are routinely assumed to have type 2. LADA progresses slowly enough that oral agents appear to work for months or years. Features that should prompt antibody and C-peptide testing include normal or low body weight, rapid onset, marked weight loss, ketones, another autoimmune condition, or failure to respond to oral therapy.
- The honeymoon phase is absent and causes real confusion when it is not explained in advance. After insulin is started, surviving beta cells often recover function, requirements fall sharply, and control becomes unusually easy for months. It does not indicate remission or misdiagnosis, and insulin is reduced rather than stopped.
- Two points on hypoglycemia, which the brief lists as a complication without detail. Severe hypoglycemia is treated with glucagon and nothing is placed in the mouth of someone who cannot swallow safely. And hypoglycemia unawareness, from repeated lows blunting the counter-regulatory response, is a major clinical problem that is partly reversible by strict avoidance of lows for several weeks.
- Euglycemic DKA belongs in the DKA section: ketoacidosis with near-normal glucose, seen particularly in pregnancy, with reduced intake, and on SGLT2 inhibitors.
- The management section would be more complete with the associated autoimmunity and the screening schedule. Autoimmune thyroid disease and coeliac disease are substantially more common in type 1 and are often silent. Complication screening covers retinopathy, urine albumin-to-creatinine ratio, foot examination, lipids and blood pressure, and cardiovascular risk is frequently under-treated in type 1 because standard risk calculators were not developed for this population.
- Finally, the evidence base for intensive control deserves naming. The DCCT showed that intensive glucose control substantially reduced microvascular complications at the cost of more severe hypoglycemia, and long-term follow-up showed the benefit persisting for decades after the groups converged, including fewer cardiovascular events. That legacy effect is the strongest argument for early control.
- Everything else in the brief is accurate: selective T-cell-mediated destruction of beta cells in the islets of Langerhans producing absolute insulin deficiency requiring lifelong exogenous insulin; the diagnostic thresholds and markers as tabulated; HLA associations including DR3 and DR4 interacting with environmental triggers; insulitis progressively destroying beta-cell mass; absolute insulin deficiency driving unchecked hepatic gluconeogenesis, glycogenolysis and lipolysis with free fatty acids converted to ketone bodies; severe hypoglycemia and DKA as the acute risks with microvascular and macrovascular complications over time; and continuous basal-bolus replacement by MDI or pump alongside frequent self-monitoring or CGM.
Download the PDF
Our reviewed pages on this
All source documents